Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA

por La Rocca, E., De Santis, M. C., Silvestri, M., Ortolan, E., Valenti, M., Folli, S., de Braud, F. G., Bianchi, G. V., Scaperrotta, G. P., Apolone, G., Daidone, M. G., Cappelletti, V., Pruneri, G., Di Cosimo, S.
Publicado 2022

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

por Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., Pruneri, G., Vingiani, A., Belfiore, A., Cappelletti, V., Vismara, M., Dell'Angelo, F., De Cecco, L., Bianchi, G.V., de Braud, F.G., Daidone, M.G., Di Cosimo, S.
Publicado 2021

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

por Guarneri, V, Dieci, M V, Bisagni, G, Frassoldati, A, Bianchi, G V, De Salvo, G L, Orvieto, E, Urso, L, Pascual, T, Paré, L, Galván, P, Ambroggi, M, Giorgi, C A, Moretti, G, Griguolo, G, Vicini, R, Prat, A, Conte, P F
Publicado 2019

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

por Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J.
Publicado 2023